Funded Study: Treatment of Canine Lymphoma University of ...
Funded Study: Treatment of Canine Lymphoma
University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory
Study Title: Study to Determine the Efficacy and Safety of Alternating Rabacfosadine and Doxorubicin
Treatments Against Multicentric Lymphoma in Previously Untreated Dogs
Purpose of Study: Non-Hodgkin lymphoma (NHL) or lymphosarcoma (LSA), the most common
hematopoietic tumor of dogs, is an aggressive disease. While the majority of dogs will respond to cytotoxic
chemotherapy utilizing a standard multi-agent (e.g. CHOP-based) approach, greater than 95% of dogs will
relapse with chemotherapy-refractory disease. The median survival time is approximately 1 year from
diagnosis.
The objective of this study is to evaluate the safety and efficacy of rabacfosadine for injection (formerly
VDC-1101/GS-9219) and doxorubicin in dogs with previously untreated spontaneous multicentric
lymphoma, when rabacfosadine for injection and doxorubicin are alternately administered every 21 days.
Inclusion Criteria:
¡ñ Histologic or cytologic diagnosis confirmatory of lymphoma
¡ñ Must have peripherally accessible and measurable disease
¡ñ Therapy na?ve, including the use of corticosteroids
¡ñ Adequate organ function indicated by standard laboratory tests
¡ñ Documentation of immunophenotype
¡ñ West Highland White Terriers are ineligible
Eligibility Diagnostics:
Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and
required to have the following diagnostics performed in their dog:
1) Diagnosis of lymphoma with histopathology or cytology, if not already documented
2) Screening blood work and urinalysis, if not performed within 7 days
3) Immunophenotype of lymphoma, if not already documented
4) Thoracic radiographs will be strongly recommended
Treatment:
Dogs will receive alternating dosages of doxorubicin and rabacfosadine once every 3 weeks for a total of 6
cumulative treatments. Each dog will have routine blood work, urinalysis, lymph node measurements, and
chest radiographs at defined scheduled reevaluations.
Compensation:
Pet owners are financially responsible for all diagnostics such as blood work and cytology required for their
pets to be deemed eligible for study recruitment. After patients have been deemed eligible, this is a partially
funded trial, and dogs will receive rabacfosadine free of cost.
Contact Information: Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at
(217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information.
Referring veterinarian and client calls are welcome.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- golden retrieverupdate
- an update to lymphoma in dogs vet times
- lymphoma in dogs diagnosis and treatment
- lymphoma in dogs
- canine lymphoma different faces with different treatment
- cutaneous epitheliotropic t cell lymphoma in canines
- managing the canine patient with lymphoma
- funded study treatment of canine lymphoma university of
Related searches
- treatment of bacterial conjunctivitis
- why study philosophy of education
- treatment of inclusion body myositis
- treatment of ed
- treatment of autoimmune diseases
- lymphoma symptoms of lymph nodes
- treatment of blepharitis of the eyelids
- treatment for malt lymphoma stomach
- symptoms of canine bloat
- treatment for canine alopecia
- lymphoma types of cancer
- symptoms of canine hypothyroidism